Chemokine Therapeutics Corp Q2 Update by Investrend Research Provider Fundamental Research.

NEW YORK -- (Investrend Research Syndicate) Fundamental Research Corp analyst Amit Bandekar has made available an update on Chemokine Therapeutics Corp (TSX: CTI, OTCBB: CHKT) in a report dated August 19, 2005. A summary of the report follows below; the full 7-Page update is available free for a limited time at www.fundamentalresearchcorp.com.

According to the report, Q2 2005 results indicate a faster pace of development with R&D expenditures growing nearly 60%. Recent developments continue to reinforce the analyst's positive outlook on the company's focused efforts to develop its two lead drug candidates. The report highlights the award of a U.S. patent to CTCE-9908 as creating significant barriers to entry for other potential competitors. Also, orphan drug designation awarded to CTCE-9908 reaffirms the analyst's faith in the novel therapeutics and unique mechanisms being employed by CTI.

Regarding recent trial results, the analyst says "We consider the safety and efficacy data from Phase I trials of CTCE-0214 as positive. We expect that PPD Inc. will exercise its option to license the molecule following the completion of Phase I studies early next year."

The analyst also notes five key risk factors including: Product Failure - the drug candidates may fail at any stage during the development process, Cash Flow/Financing - if CTI is not able to secure financing before revenues are generated, it will not be able to continue operating beyond two years, Regulatory - the company may face regulatory delays in product approvals (NDA) or other stages. Dilution - the company has been covering basic expenses by issuing equity which may dilute existing shareholders, and Competition - the initial successes of the drug candidates may attract competitors who seek to develop similar classes of drugs.

Fees of less than $25,000 have been paid by the subject company to FRC. FRC and Investrend Research subscribe to the "Standards For Independent Research Providers" at http://www.firstresearchconsortium.com, and also take steps to ensure independence including setting fees in advance and utilizing analysts who must abide by CFA Institute Code of Ethics and Standards of Professional Conduct. Additionally, analysts may not trade in any security under coverage.

Complete information about this company is available at the company's InvestorPower page, and the full report is available at: http://www.fundamentalresearchcorp.com/and http://www.investrendresearch.com Investors are advised to read disclosures carefully before trading in the equities of any enrolled company.

Anyone interested in receiving alerts regarding Chemokine research should email [e-mail] and [e-mail] with "CTI" in the subject line.